Background: Estrogen receptor (ER) positive breast cancer is often effectively treated with 36 drugs that inhibit ER signaling, i.e., tamoxifen (TAM) and aromatase inhibitors (AIs). 37
Introduction 69
Breast cancer is among the most common cancers diagnosed in women in Europe where it 70 also is the third cause of cancer death after lung and colorectal cancer (1) . Approximately 71 75% of breast cancers is characterized by the expression of estrogen receptor alpha (ERα), 72 encoded by the estrogen receptor 1 (ESR1) gene. These tumours require estrogen signals 73 for continued growth and, consequently, patients generally receive endocrine treatment to 74 inhibit ER signalling (2) Endocrine treatment comprises selective estrogen receptor 75 modulators, including tamoxifen, selective estrogen receptor down-regulators including 76 fulvestrant, and aromatase inhibitors (e.g., anastrozole, letrozole and exemestane) that 77 inhibit the production of estrogen from androgen. Unfortunately, resistance to endocrine 78 therapy develops in approximately 30% of ER+ breast cancer patients resulting in recurrence 79 of the tumour (3) . Despite many efforts the precise mechanisms leading to acquired 80 treatment resistance remain mostly unknown and, hence, therapies to prevent or revert 81 resistance are currently lacking. Therefore, the identification of biomarkers, including 82 epigenetic markers, that can predict endocrine resistance are considered of great value for 83 patient stratification prior to endocrine therapy (4) . 84
In general, breast cancer development, progression and (endocrine) drug resistance result 85 from the cumulative burden of genetic and epigenetic changes. Moreover, post-86 transcriptional and post-translational modifications are likely to contribute as well (5) (6) (7) . 87
The association of epigenetic changes with tumour characteristics, subtypes, prognosis, and 88 treatment outcome is not well characterized (8) . Epigenetic changes have been shown to 89 drive resistance acquisition through their effect on gene expression and/or chromosomal 90 stability (9) . For example, using RNA-seq and ChIP-seq analysis of the acetylation of lysine 91 27 on histone 3 (H3K27ac), an established active enhancer marker, revealed that epigenetic 92 activation of the cholesterol biosynthesis pathway causes activation of ERα resulting in 93 resistance (10) . DNA methylation has also been shown to be perturbed during breast cancer 94 development and may largely affect gene expression (4, 11) Since DNA methylation has also 95 been shown to be altered in endocrine resistant tumours (12) the identification of methylation 96 markers for disease diagnosis, prognosis, and treatment outcome is receiving increased 97 attention. Moreover, breast cancer treatment might benefit from the regulation of methylation 98 activity by using DNA methyltransferase inhibitors (4) . Treatment with the DNA 99 methyltransferase inhibitor 5-aza-2' deoxycytidine caused a significant reduction in promoter 100 methylation and a concurrent increase in expression of the gene ZNF350 that encodes a 101 DNA damage response protein, and of MAGED1 which is a tumour antigen and putative 102 regulator of P53, suggesting that a methylation-targeted therapy might be beneficial (13) . inactivated by cytidine deaminase thus limiting their use in the treatment of breast cancer 105 (14) . 106
Several studies investigated DNA methylation in relation to disease outcome and therapy 107 resistance. Lin et al. observed significant differences in DNA methylation profiles between 108 tamoxifen sensitive and tamoxifen resistant cell lines (15) . There, a large number of genes, 109 several of which have been previously implicated in breast cancer pathogenesis, were shown 110 to have increased DNA methylation of their promoter CpG islands in the resistant cell lines. 111
Similarly, Williams et al. observed a large number of hypermethylated genes in a tamoxifen-112 resistant cell line (13) . In a meta-analysis of two human breast cancer gene expression 113 datasets, 144 abnormally methylated genes were shortlisted as putative epigenetic 114 biomarkers of survival. Kaplan-Meier survival analysis on the expression of these genes 115 further reduced this list to 48 genes, and a subsequent correlation analysis of gene 116 expression and DNA methylation provided evidence for the potential association of DNA 117 methylation with survival in different breast cancer subtypes including ER+/HER2- (16) . 118
Another study compared ductal carcinoma in situ to invasive breast cancer and suggested 119 that methylation changes indicate an early event in the progression of cancer and, therefore, 120 might be of relevance for clinical decision making (17) . In contrast to studies that showed the 121 impact of promoter methylation, it has also been demonstrated that endocrine response in 122 cell lines is mainly modulated by methylation of estrogen-responsive enhancers (18) . There, 123 increased ESR1-responsive enhancer methylation in primary tumours was found to be 124 associated with endocrine resistance and disease relapse in ER-positive (luminal A) human 125 breast cancer, suggesting that methylation levels can be used to identify patients that 126 positively respond to endocrine therapy. Note that, although limited ER-responsive enhancer 127 methylation may already be present in the primary tumour, the analysis of methylation 128 profiles of matched relapse samples showed that enhancer DNA methylation increased 129 during treatment. Therefore, a combination of pre-existing and acquired differences in 130 enhancer DNA methylation could be associated with the development of endocrine therapy 131 resistance. 132
In the current work we investigated if DNA methylation profiles of primary ER+/HER2-133 tumours provide information to predict endocrine resistance. We selected methylation 134 profiles provided by The Cancer Genome Atlas (TCGA) (19) from patients treated with 135 tamoxifen or aromatase inhibitors, and assumed that patient survival is a proxy for absence 136 of therapy resistance. To identify specific DNA methylation markers we tested the 137 association with survival using a Cox proportional hazards model. We were able to identify 138 DNA methylation markers associated with patient outcome. We validated these markers 139 using DNA methylation profiles generated in a time course experiment using the T47D cell 140 line treated with tamoxifen or deprived from estrogen.
Materials and methods 144
Data 145
We used clinical, biospecimen, gene expression (RNAseq V2) and DNA methylation 146 (Illumina Human Methylation 450K) data of 1,098 patients with breast invasive carcinoma 147 (BRCA) from TCGA (cancergenome.nih.gov). Samples represented in TCGA were all 148 collected prior to adjuvant therapy (20) . TCGA also recorded patient follow-up information 149 describing clinical events such as type of treatment, the number of days from the date of 150 initial pathological diagnosis to a new tumour event, death, and date of last contact. Since 151 clinical and biospecimen data are scattered over multiple files in the TCGA repository, we 152 first merged all information in a single table with one row per patient using the patient 153 identifiers provided in the clinical and biospecimen data. Subsequently, we corrected drug 154 names for tamoxifen and aromatase inhibitors (AIs; anastrozole, exemestane and letrozole) 155 for spelling variants and mapped synonyms to their generic drug names (Additional File 1). 156
We selected the subset of patients (samples) that were treated with AI or tamoxifen. 157 158
Patient cohorts 159
For all patients with DNA methylation data available we selected data from primary tumours 160 (indicated with "01" in the patient barcode) of female ER+/HER2-BRCA patients (Figure 1 ). 161
The molecular subtype was determined using TCGA gene expression data for these samples 162 (see below). The ER+/HER2-cohort was further subdivided according to the endocrine 163 treatment (AI or tamoxifen) patients received during follow-up. Patients who received both 164 drugs were included in both sub-cohorts. Consequently, we considered three patient cohorts, 165
i.e., ER+/HER2-, AI, and tamoxifen (TAM). 166 167
Subtype determination 168
Information for BRCA subtyping by immunohistochemistry of ER or HER2 is missing for 192 169 out of 1,098 patients. Therefore, we used TCGA BRCA RNAseq V2 gene expression data to 170 determine molecular subtypes (Additional File 2). To this end, gene expression data from 171 primary tumours were retrieved from the Genomic Data Commons legacy archive 172 (https://portal.gdc.cancer.gov/legacy-archive) using the R package TCGAbiolinks (21) . 173 RSEM estimated abundances were normalised using the upper quartile method from the R 174 package edgeR (22) and subsequently log2-transformed with an offset of one. Breast cancer 175 subtypes ER-/HER2-, HER2+, and the lowly proliferative ER+/HER2-(luminal A) and highly Illumina Human Methylation 450K raw data (IDAT files) for the patients in the cohorts defined 181 above were retrieved from TCGA. Pre-processing was performed using the R package minfi 182 (24) . Detection p-values were calculated for each methylation probe. 82,150 probes showed 183 an unreliable signal (p>0.01) in one or more samples and were removed. Data were 184 normalized using functional normalization (25) . Probes corresponding to loci that contain a 185 SNP in the CpG site or in the single-base extension site were removed. We also removed 186 probes that have been shown to cross-hybridize to multiple genomic positions (26) . 
Multi-locus survival analysis 226
We used the Cox proportional hazards model with elastic net regularization (function 227 cv.glmnet, R package glmnet) (31) to identify a signature of multiple methylation loci 228 associated with survival. We followed a two-stage approach. First, the CpG signature was 229 determined without including clinical variables using Cox regression with elastic net penalty. 230
Secondly, from the resulting model the risk score (see below) was calculated and used in a 231 new model that includes the clinical variables selected above in order to establish whether 232 the methylation signature provided additional information compared to merely using clinical 233 variables. Optimal values, minimizing the partial likelihood deviance, for the elastic net mixing 234 parameter (α) and tuning parameter (λ) were determined by stratified (for event status) 10-235 fold cross-validation using a grid search varying α from 0 to 1 in steps of 0.1 and using 100 236 values for λ that were automatically generated for each α. We constructed one model for 237 each of the three cohorts (ER+/HER2-, AI, TAM). Subsequently, for each cohort we used the 238 identified signature to calculate a risk score for each patient: 239
where for CpG locus i, c i denotes the corresponding coefficient in the Cox model and M i the 240 methylation M-value. Next, multivariable Cox proportional hazards regression was performed 241 using the risk score as a variable and adjusting for significant clinical variables from the 242 multivariable model. Missing values for the clinical variables were imputed as described 243 above. Finally, the risk-score-based models were also adjusted for ER+/HER2-subtypes 244 (luminal A/luminal B) in addition to the selected clinical variables. Kaplan-Meier curves were 245 determined for two groups of patients by calculating the median of the risk scores over all 246 patients in a cohort and then assigning a patient to a good (risk score < median) and a bad 247 prognosis group (risk score ≥ median). 248
To assess the stability of the multi-locus signatures 50 regularized Cox models were fitted 251 using a stratified (for event status) selection of 90% of the samples for each cohort. We 252 counted the number of times each CpG locus was included in the 50 signatures and then 253 selected those CpGs that occurred in at least 10 or at least 35 signatures. We refer to the 254 resulting signatures as stability signatures. Fisher's exact test was used to determine the 255 significance of the overlap between the original multi-locus signature and the stability 256 
Results 297
Clinical variables are associated with survival in ER+/HER2-cohort 298
For the TCGA BRCA ER+/HER2-cohort (N=552, Figure 1) we assessed whether the clinical 299 variables menopause status, AI treatment, tamoxifen treatment, tumour stage and age at 300 diagnosis were associated with survival, with an event defined as first occurrence of a new 301 tumour event or death. In a univariable Cox proportional hazards model tumour stage (HR 302 1.92, 95% CI 1.43-2.59; p=1.63E-05) and age at diagnosis (HR 1.03, 95% CI 1.01-1.05; 303 p=2.40E-04) are significantly associated with survival (Table 1A) . This is in agreement with 304 previous findings that a more advanced tumour stage and increased age are associated with 305 poorer outcome (35) .Tamoxifen treatment, AI treatment and menopause status are not 306 significantly associated with survival in our cohort. When we included the clinical variables in 307 a multivariable Cox proportional hazards model, tumour stage, age and AI treatment were 308 selected for inclusion in the final multivariable model using backward selection (Table 1B) . exact test). The risk score calculated from the multi-locus signature and adjusted for tumour 335 stage, age and AI treatment (ER+/HER2-cohort only) is significantly associated with survival 336 (p<10E-5) for all three cohorts (Additional File 8) indicating that DNA methylation is an 337 independent factor in predicting survival. The risk scores calculated from the multi-locus 338 signatures stratify the patients in two groups for each cohort ( Figure 3A) . 339
There is no overlap between the signatures of TAM and AI cohorts. However, the 340 ER+/HER2-signature partly overlaps with the TAM and AI signatures ( Figure 3B ). The 341 coefficients in the Cox models corresponding to the overlapping loci have an identical sign in 342 both cohorts. The multi-locus signatures include a large number of methylation loci that were 343 also identified in the corresponding single-locus survival analysis. 41 out of 171 methylation 344 loci in the ER+/HER2-multi-locus signature were also found in the single-locus signature 345 (Additional File 9). Moreover, all methylation loci in the TAM and AI single-locus signatures, 346 nine and one respectively, are part of the corresponding multi-locus signature. 347
We assessed the stability of the multi-locus signatures using a 10% leave-out test. The Table  355 2). The signatures are not enriched at earlier time points. However, the proportion of CpGs 356 contributing to enrichment in the same direction ('up') increases over time until it becomes 357 significant for the last time point. The single-locus AI signature consists of only one CpG and 358 an enrichment analysis is therefore not possible. However, for this locus the change in 359 methylation level when comparing LTED treated cells with WT baseline is not concordant 360 with the log-hazard ratio for that locus (data not shown). 361
The multi-locus survival signatures for ER+/HER2 and AI are also significantly enriched at 362 the 7-month time point in the resistance acquisition experiment ( Table 3 ). The multi-locus 363 TAM signature is not significantly enriched at any time point. 364 365 tumours can be used to predict development of resistance to endocrine therapy in two sub-369 cohorts of patients treated with tamoxifen or AI. Using a single-locus Cox proportional hazard 370 model we were able to identify 132, 9 and 1 CpGs for which DNA methylation is significantly 371 associated with survival in the ER+/HER2-, TAM and AI cohorts respectively, while the 372 corresponding multi-locus signatures consisted of 171, 50 and 160 CpGs. The multi-locus 373 signatures showed a large overlap of 31%, 100%, and 100% with the ER+/HER2-, TAM and 374 AI single-locus signatures respectively. The risk scores of the multi-locus signatures were 375 significantly associated with survival. Moreover, we found that the ER+/HER2-and TAM 376 single-locus and multi-locus signatures were significantly enriched for CpGs in enhancer 377 regions suggesting a functional effect (on gene expression) (18) . For both the single-locus 378 signatures (Additional File 6) and the multi-locus signatures ( Figure 3A) we observed no 379 overlap of loci associated with survival between the AI and TAM cohorts. This could be 380 indicative of a difference in development of resistance against tamoxifen or AI. This is in line 381 with earlier observations in endocrine-resistant cells compared with wild type MCF7 cells, 382 which also showed limited overlap in their response to tamoxifen and estrogen deprivation in 383 terms of their gene expression (10) and DNA methylation profiles (18) . 384
In our analyses we adjusted for clinical variables associated with survival (tumour stage, age 385 and AI treatment (ER+/HER2-cohort only)) in order to estimate the independent effect of 386 methylation on survival. It has been shown that methylation profiles can discriminate 387 between the ER+/HER2-subtypes luminal A and B (36) . Moreover, patients with a luminal B 388 tumour have worse prognosis compared to patients with a luminal A tumour (37) , which is 389 also the case in our ER+/HER2-cohort (HR 2.04, 95%CI 1.11-3.74, p=0.020). We, therefore, We note that although the methylation profiles provided by TCGA are measured in untreated treatment information may not be complete (20) . These aspects were not taken into account 406 in our analyses and might have biased the results. We also acknowledge that this study is 407 limited by the relatively modest number of events (i.e., new tumour event, death) for the 408 different cohorts (ER+/HER2-: 97 events in 552 patients; TAM: 24 events in 172 patients; AI: 409 32 events in 210 patients) due to the relatively short follow-up time. This affects statistical 410 power to identify methylation loci associated with survival. 411
412
In this study we assumed that the methylation events in the primary tumour, rather than 413 acquired methylation during tumour progression, are associated with patient survival as a 414 proxy for development of therapy resistance. To validate our results we aimed to use 415 methylation profiles from the International Cancer Genome Consortium (ICGC; 416 https://icgc.org). However, the number of patients in the ICGC breast cancer cohort with 417 reliable information on endocrine treatment was too small to make such a comparison 418 meaningful. Instead, we used DNA methylation measurements obtained from T47D cells as 419 a model system for resistance acquisition in ER+ luminal A breast cancer. We showed that 420 our single-locus signatures for the ER+/HER2-and TAM cohorts were conserved among the 421 loci that are differentially methylated in endocrine-resistant T47D cells. Similarly, our multi-422 locus signatures for the ER+/HER2-and AI cohorts were also significantly enriched in the 423 T47D experiment. Although this is not a final validation of our results, it strongly suggests 424 that the loci we identified from primary tumours, that is prior to any endocrine treatment, are 425 also associated with endocrine resistance. 426 Stone et al. (18) recently demonstrated in a small cohort of patients who received endocrine 427 treatment for at least five years that methylation levels in selected ESR1-enhancer loci were 428 significantly increased in primary tumours of patients who relapsed within six years as 429 compared to patients with 14-year relapse free survival. Moreover, these differences were 430 even more pronounced in matched local relapse samples. DNA methylation data measured 431 in a large number of pre-and post-treatment samples obtained from patients who received 432 endocrine therapy that either relapsed due to endocrine therapy resistance or remained 433 relapse-free will enable validation of the signatures identified in this and other studies. 434
Moreover, such a cohort enables comparison of methylation levels in paired primary and 435 local relapse samples providing the opportunity to identify epigenetic drivers of endocrine 436 therapy resistance (38) . 'Up' therefore corresponds to changes in the same direction in the survival signature and in the resistance acquisition experiment. That is, if a locus is risk in/decreasing in the survival signature than it is hyper/hypomethylated in the cell line signature for the indicated time point as compared to WT baseline. 'Down' corresponds to changes in the opposite direction.
Prop., proportion of loci in the signature contributing to the estimated p-value and direction.
Significant p-values (<0.05) are indicated in bold. 
ER+/HER2-(159 CpG sites)

FIGURE 1
No tamoxifen/AI treatment: N=212 AI cohort ‡ : N=210 (32 events) ‡ 42 patients received both tamoxifen and AI and are included in both cohorts. No missing data for TAM and AI cohorts.
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